Ashton Thomas Private Wealth LLC Lowers Stock Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Ashton Thomas Private Wealth LLC reduced its position in ADMA Biologics, Inc. (NASDAQ:ADMA) by 24.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 17,034 shares of the biotechnology company’s stock after selling 5,458 shares during the quarter. Ashton Thomas Private Wealth LLC’s holdings in ADMA Biologics were worth $341,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the company. Assenagon Asset Management S.A. raised its holdings in shares of ADMA Biologics by 2.7% in the 3rd quarter. Assenagon Asset Management S.A. now owns 3,474,455 shares of the biotechnology company’s stock worth $69,454,000 after purchasing an additional 92,281 shares during the period. Seven Eight Capital LP acquired a new stake in ADMA Biologics during the 2nd quarter worth approximately $1,992,000. Louisiana State Employees Retirement System purchased a new position in ADMA Biologics in the third quarter valued at approximately $2,253,000. Point72 Asset Management L.P. acquired a new position in ADMA Biologics during the second quarter valued at approximately $1,157,000. Finally, New York State Teachers Retirement System purchased a new stake in ADMA Biologics during the third quarter worth approximately $1,821,000. Institutional investors and hedge funds own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on ADMA. Cantor Fitzgerald reissued an “overweight” rating and issued a $20.00 target price on shares of ADMA Biologics in a research note on Friday, September 20th. HC Wainwright raised their price objective on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James upped their target price on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

ADMA Biologics Trading Down 5.9 %

NASDAQ ADMA opened at $20.20 on Friday. The stock has a market cap of $4.71 billion, a P/E ratio of 72.14 and a beta of 0.64. The company’s fifty day simple moving average is $18.42 and its 200-day simple moving average is $14.22. The company has a current ratio of 7.09, a quick ratio of 3.26 and a debt-to-equity ratio of 0.48. ADMA Biologics, Inc. has a 52 week low of $3.60 and a 52 week high of $23.64.

ADMA Biologics (NASDAQ:ADMA) last issued its quarterly earnings data on Thursday, November 7th. The biotechnology company reported $0.15 EPS for the quarter, topping analysts’ consensus estimates of $0.13 by $0.02. The firm had revenue of $119.84 million for the quarter, compared to analyst estimates of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same quarter in the previous year, the business posted $0.01 EPS. Equities research analysts predict that ADMA Biologics, Inc. will post 0.52 EPS for the current fiscal year.

Insider Activity at ADMA Biologics

In other ADMA Biologics news, Director Young Kwon sold 60,000 shares of the firm’s stock in a transaction on Friday, August 23rd. The shares were sold at an average price of $18.26, for a total transaction of $1,095,600.00. Following the completion of the transaction, the director now directly owns 241,441 shares of the company’s stock, valued at $4,408,712.66. This trade represents a 19.90 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Lawrence P. Guiheen sold 9,000 shares of the company’s stock in a transaction dated Monday, September 9th. The shares were sold at an average price of $18.47, for a total transaction of $166,230.00. Following the completion of the sale, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. This trade represents a 5.52 % decrease in their position. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 466,900 shares of company stock valued at $8,224,121. Insiders own 3.70% of the company’s stock.

ADMA Biologics Company Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.